Healthcare bodies promoting economic driven off-label use when licensed alternatives exist, as reflected in recent legislative changes in France and Italy, undermine the European regulatory framework, potentially compromise patient safety and create legal uncertainty. Such practices may lead to “secondary, national marketing authorizations”, thereby undermining the EU regulatory framework as developed over the past 20 years, as well as putting into question the European Commission’s competence to authorize new medicines. 

Read the full position paper